Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07561645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

Study acronym: ALPINE 2
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 2026 to Sep 2026v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum/Etoposide) in LCNEC.
Trial Details
NCT Number NCT07561645
Lead Sponsor Technische Universität Dresden
Conditions
(from sponsor)		 Large Cell Neuroendocrine Carcinoma of the Lung
Related terms Carcinoma, Neuroendocrine, Lung Neoplasms
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov